Tryp Therapeutics Inc.
TRYPF · OTC
8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $3 | $1 | $0 |
| G&A Expenses | $2 | $4 | $4 | $0 |
| SG&A Expenses | $2 | $4 | $6 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $2 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $7 | $7 | $0 |
| Operating Income | -$5 | -$7 | -$6 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$0 | -$1 | $0 |
| Pre-Tax Income | -$5 | -$7 | -$8 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$7 | -$8 | -$0 |
| % Margin | – | – | – | – |
| EPS | -0.055 | -0.096 | -0.12 | -0.011 |
| % Growth | 43.1% | 20% | -990.9% | – |
| EPS Diluted | -0.055 | -0.096 | -0.12 | -0.011 |
| Weighted Avg Shares Out | 96 | 78 | 67 | 38 |
| Weighted Avg Shares Out Dil | 96 | 78 | 67 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$7 | -$6 | $0 |
| % Margin | – | – | – | – |